Didier TronoAprès des études de médecine à l’Université de Genève et une formation clinique en pathologie, médecine interne et maladies infectieuses à Genève et au Massachusetts General Hospital de Boston, Didier Trono s’engage dans une carrière scientifique au Whitehead Institute du MIT. En 1990, il est recruté par le Salk Institute de San Diego pour lancer un centre de recherche sur le SIDA. Il rentre en Europe sept ans plus tard, avant de prendre en 2004 les rênes de la toute nouvelle faculté des Sciences de la Vie de l’EPFL, dont il orchestre le développement et qu’il dirige jusqu’en 2012. Il participe aujourd’hui activement à la coordination des efforts de la Suisse en vue de l’intégration des nouvelles technologies dans le domaine de la médecine de précision et de la santé personnalisée.
Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Sandro CarraraSandro Carrara a été nommé IEEE Fellow pour ses remarquables réalisations dans le domaine de la conception de biocapteurs CMOS à l'échelle nanométrique. Il a également reçu le prix "IEEE Sensors Council Technical Achievement Award" en 2016 pour son leadership dans le domaine émergent du co-design des interfaces Bio/Nano/CMOS. Il est un Professeur titulaire à l' EPFL à Lausanne (Suisse) et responsable du groupe de recherche "Bio/CMOS Interfaces" (BCI). Il est ancien professeur de biocapteurs optiques et électriques au Département de génie électrique et de biophysique (DIBE) de l'Université de Gênes (Italie) et ancien professeur de nanotechnologie à l'Université de Bologne (Italie). Il est titulaire d'un doctorat en biochimie et de biophysique de l'Université de Padoue (Italie), une master en physique de l'Université de Gênes (Italie), et un diplôme en électronique de l'Institut National de Technologie à Albenga (Italie). Ses intérêts scientifiques sont sur les phénomènes électriques de films nano-bio-structuré, et comprennent CMOS conception de biopuces à base de protéines et de l'ADN. Le long de sa carrière, il a publié 7 livres, l'un comme auteur avec Springer sur les interfaces Bio/CMOS et, plus récemment, un manuel de bioélectronique avec La prestigieuse Cambridge University Press. Il a également publié plus de 250 articles scientifiques et est l'auteur de 13 brevets. Il est maintenant chef rédacteur du Journal IEEE Sensors; il est également fondateur et chef rédacteur du Journal BioNanoScience par Springer, et rédacteur adjoint de IEEE Transactions on Circuits and Biomedical Systems. Il est membre du IEEE Sensors Council et de son comité exécutif. Il était membre du Conseil des gouverneurs de la IEEE Circuits And Systems Society (CASS). Il a été nommé IEEE conférencier émérite pour les années 2017-2019 pour le Conseil IEEE Sensors, et de la société CASS pour les années 2013-2014. Son travail a reçu plusieurs reconnaissances internationales: plusieurs Top-25 Hottest-articles (2004, 2005, 2008, 2009, et deux fois en 2012) publiés dans des journaux internationales très fort impact telles que Biosensors and Bioelectronics, Sensors And Actuators B, IEEE Sensors, et Thin Solid Films; un Award à une conference de l'OTAN en 1996 pour la contribution originale à la physique de la conductivité à électron unique dans les nano-particules; six "Best Paper Awards" pour des articles présentés à la conférence IEEE Sensors Conference en 2019 (Montreal), IEEE NGCAS en 2017 (Genoa), MOBIHEALTH en 2016 (Milan), IEEE PRIME en 2015 (Glasgow), en 2010 (Berlin) et en 2009 (Cork), un prix de la meilleure affiche au rencontre annuel de Nanotera en 2011 (Berne), et un prix de la meilleure affiche au NanoEurope Symposium en 2009 (Rapperswil). De 1997 à 2000, il a été membre d'un comité international au ELETTRA Synchrotron à Trieste. De 2000 à 2003, il était responsable scientifique d'un Programme national de recherche (PNR) dans le dépôt de nanobiotechnologie. Il était un expert internationalement estimé du comité d'évaluation de l'Académie de Finlande dans un programme de recherche pour les années 2010-2013. Il a été le président général (General Chair) de la Conférence IEEE BioCAS 2014, le premier conférence internationale dans le domaine des circuits et des systèmes pour les applications biomédicales.
Christian DepeursingeChristian Depeursinge is the leader of the Microvision and Micro-Diagnostics (MVD) group at the Advanced Photonics Laboratory of the Institute of Microengineering at EPFL (Ecole Polytechnique Fédérale de Lausanne), Switzerland (http://apl.epfl.ch/muvision). His research and expertise in biomedical engineering and optics is internationally acknowledged. His current research topics include coherent and incoherent Imaging applied to diagnostics in biology, His research group pioneered in the development of DHM technology. He worked on several projects developed in cooperation with European and international partners. He is author and co-author of over 100 papers published in peer reviewed journals, several book chapters and more than 30 patents. He has given more than 20 invited lectures and plenaries in the last five years. He developed many projects in cooperation with national and international industries. He is co-founder of a start-up company (Lyncée Tec SA: www.Lynceetec.com). He is currently teaching at EPFL and occasionally in foreign universities and institutes. Pierre VogelProfessional positions:
P. Vogel was born in Cully (Switzerland) Oct. 23, 1944. In 1969, he did his Ph.D Award under supervision of Prof. H. Prinzbach at the Institute of Organic Chemistry, University of Lausanne. After finishing his Ph.D in 1969, he did post-doctoral research at Yale University, New Haven, Connecticut, USA with Prof. Martin Saunders; research associate with Prof. J. A. Berson, K. A. Wiberg and P.v.R. Schleyer (Princeton Universtiy). From 1971 he worked as a Research chemist at Syntex S.A., in Mexico with Prof. P.Crabbé before he returned to the University of Lausanne in 1972. As of 1977 he became Professor of organic chemistry at the University of Lausanne. In 1991 he was Vice-Chairman of the Institute of organic Chemistry, University of Lausanne until 2001. Then he was Part-time grad.school teacher at the Universitites of Rouen and Caen from 1991 to 1993 and Part-time professor at Ecole Polytechnique de Palaiseau from 1993-2000. From 2000-2001 he was reviewer of the "Institut Universitaire de France" and as of 2001 Professor of organic chemistry at the EPFL.
Degrees and distincions
1969 Ph.D, University of Lausanne
1976 Swiss Chemical Society Award, Werner Medal
1973-now Member of the Swiss Chemical Society, of the American Chemical
Society and "Société Française de Chimie"
1984-1989 IOCD adviser
1988-1989 Associate Professor of Organic Chemistry at Ecole Normale
Supérieure, Paris
1989-2000 Member of the Swiss National Council of Research
1991-1992 Associate Professor of Organic Chemistry, University of Paris VI
1992 Pacific Coast Lecturer (USA)
1992-1993 Associate Professor at the Université de Montpellier, France
1993 Associate Professor, Université Paris Sud, Orsay
1993-1997 Swiss co-ordinator of the European COST D2 research program
1994 (spring) Associate Professor, ESPCI, Paris
1997 President of the european COST D2 management committee
1999 Coordinator of the european COSRD13
2001-now Member of the "Conseil Scientifique du Département des Sciences
Chimiques", CNRS
2002-2003 Novartis Lectureship
2004-2005 Boehringer INgelheim Distinguished Lecturer
Cathrin BriskenCathrin Brisken, MD, PhD, is Associate Professor of Life Sciences at the Swiss Federal Institute of Technology Lausanne (EPFL). Dr. Brisken is internationally recognized for her work on endocrine control of mammary gland development and breast carcinogenesis.
Dr. Brisken received her MD and her PhD degree in Biophysics from the Georg August University of Göttingen, Germany. She completed her postdoctoral work in cancer biology with Dr. R.A. Weinberg at the Whitehead Institute of Biomedical Research in Cambridge, MA, USA. She previously held appointments at the Cancer Center of the Massachusetts General Hospital, Harvard Medical School, Boston and the Swiss Institute for Experimental Cancer Research (ISREC).
Research in Dr. Brisken’s laboratory focuses on the cellular and molecular underpinnings of estrogen and progesterone receptor signaling in the breast and the respective roles of these hormones and hormonally active compounds in carcinogenesis. The aim is to understand how recurrent exposures to endogenous and exogenous hormones contribute to breast carcinogenesis in order to better prevent and treat the disease. The laboratory has pioneered in vivo approaches to genetically dissect the role of the reproductive hormones in driving mouse mammary gland development and shown how they control intercellular communication. Dr. Brisken’s group has developed ex vivo and humanized mouse models using patient samples to study hormone action in human tissues in normal settings and during disease progression.
Dr. Brisken is member of the International Breast Cancer Study Group (IBCSG) Biological Protocol Working Group. She served as Dean of EPFL Doctoral School (more than 2000 PhD students in 18 PhD programs), as member of the Hinterzartener Kreis, the oncology think-tank associated with the German Science Foundation, and numerous Swiss, European, and AACR committees. She co-founded the International Cancer Prevention Institute.
Matthias LütolfMatthias Lutolf is Full Professor at EPFL’s Institute of Bioengineering, with a cross appointment in the Institute of Chemical Sciences and Engineering. Lutolf was trained as a Materials Engineer at ETH Zurich where he also carried out his PhD studies (with Jeffrey Hubbell) that were awarded with an ETH medal. He continued his research training as a Post-Doctoral Fellow in Stem Cell Biology (with Helen Blau) at Stanford University. He has served as the Director of the Institute of Bioengineering from 2014 to 2018. Lutolf is an internationally recognized leader in the fields of stem cell bioengineering and tissue engineering. His research program uniquely combines stem cell biology with engineering principles and quantitative thinking. His team, composed of engineers, chemists, physicists, cell and developmental biologists, strives to develop technologies that have true biological and medicinal function and applicability. Lutolf’s work has led to more than 110 peer-reviewed scientific publications, many of which published in highly reputed journals, more than 25 patents, and the commercialization of several products. Current research in the Lutolf lab is focused on the bioengineering of miniature tissues, termed organoids, that are generated from self-organizing stem cells.
